Does the antisecretory peptide AF-16 reduce lung oedema in experimental ARDS?

Background: Acute respiratory distress syndrome (ARDS) is an acute inflammatory condition with pulmonary capillary leakage and lung oedema formation. There is currently no pharmacologic treatment for the condition. The antisecretory peptide AF-16 reduces oedema in experimental traumatic brain injury...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrueta Tenhunen, Annelie, Massaro, Fabrizia, Hansson, Hans Arne, Feinstein, Ricardo, Larsson, Anders, Perchiazzi, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968528/
https://www.ncbi.nlm.nih.gov/pubmed/31701794
http://dx.doi.org/10.1080/03009734.2019.1685029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968528/
https://www.ncbi.nlm.nih.gov/pubmed/31701794
http://dx.doi.org/10.1080/03009734.2019.1685029

Ejemplares similares